Levetiracetam Stragen (Levetiracetam)

Levetiracetam binds to the synaptic vesicle protein SV2A, which modulates neurotransmitter release. This action stabilizes neuronal firing and lowers hyperexcitability, helping to prevent the spread of seizure activity without directly influencing ion channels.

The appropriate dose of Levetiracetam Stragen is determined by the prescribing clinician based on the patient’s age, weight, renal function, and seizure type. Dosage regimens are individualized and should follow the prescriber’s instructions.

Safety data for Levetiracetam during pregnancy and lactation are limited. The medication should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and decisions should be made in consultation with a healthcare professional.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and import documentation.

Levetiracetam offers a distinct mechanism (SV2A binding) and generally has fewer drug‑enzyme interactions than older agents such as carbamazepine or phenytoin. It is often preferred for patients who require rapid intravenous control or who have experienced adverse effects with other antiepileptics.

Levetiracetam Stragen should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture and direct light. Do not freeze the solution, and inspect it for particulate matter before administration.

The product is supplied as an intravenous solution and is administered by slow infusion under medical supervision. The infusion rate and total daily dose are set by the treating physician according to the patient’s clinical condition.

Serious risks include severe allergic reactions (rash, swelling, breathing difficulty), significant mood or behavioral changes such as depression or suicidal thoughts, and rare hematologic abnormalities like low white‑blood‑cell or platelet counts. Prompt medical attention is required if any of these occur.

Patients with a known hypersensitivity to levetiracetam or any component of the formulation should avoid its use. Caution is also advised for individuals with severe renal impairment, as dose adjustment may be required, and for those with a history of serious psychiatric disorders.